title: Effective treatments for paronychia caused by oncology pharmacotherapy.
abstract: Cutaneous adverse events are relatively common in patients being treated with molecular-targeted drugs. Paronychia is one of the cutaneous adverse events that influences the patient's quality of life because of pain, and it often affects anticancer treatments in severe cases. However, there are few effective treatments, especially for severe paronychia. Here, we present our experiences of treatment for paronychia due to oncology pharmacotherapy. Although we treated paronychia with various methods, only corticosteroid ointment and phenol chemical matricectomy significantly improved the paronychia. Dermatologists must perform appropriate and effective treatments for paronychia in order to enable patients to continue anticancer drug treatment without impairing their quality of life.
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.|Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Goto
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Shusuke
authors.initials: S
authors.lastname: Yoshikawa
authors.affiliation: Clinical Research Promotion Unit, Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Keita
authors.initials: K
authors.lastname: Mori
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Otsuka
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Omodaka
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Yoshimi
authors.affiliation: Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yoshida
authors.affiliation: Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Tottori, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Yamamoto
authors.affiliation: Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kiyohara
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010304:Paronychia / Q000139:chemically induced / Q000188:drug therapy*; D019800:Phenol / Q000627:therapeutic use*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D009824:Ointments; D012597:Sclerosing Solutions; D019800:Phenol
keywords: combination therapy; cutaneous adverse event; oncology pharmacotherapy; paronychia; quality of life